Literature DB >> 18294823

Statin induced myotoxicity: the lactone forms are more potent than the acid forms in human skeletal muscle cells in vitro.

Ine Blankenberg Skottheim1, Ane Gedde-Dahl, Solmaz Hejazifar, Kjersti Hoel, Anders Asberg.   

Abstract

Statins exist in both acid and lactone forms in vivo. High plasma levels of the lactone forms have been observed in patients with statin induced myopathy. In the present study, the hypothesis that lactone forms have a higher potency of inducing myotoxicity as compared to acid forms was investigated. Primary human skeletal muscle cells were incubated with increasing concentrations of lactone and acid forms of atorvastatin, fluvastatin, pravastatin and simvastatin. Following incubation, living myotubes were quantified by fluorescence staining. Atorvastatin lactone showed a 14-fold, fluvastatin lactone a 26-fold, pravastatin lactone a 23-fold, and simvastatin lactone a 37-fold higher potency to induce myotoxicity compared to their corresponding acid forms. Thus, for the four different statins the present study shows a significantly higher potency of the lactone forms, than the respective acid forms, to induce myotoxicity in human skeletal muscle cells in vitro. These results clearly indicate the need to differentiate between acid and lactone forms in future investigation of statin myotoxicity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18294823     DOI: 10.1016/j.ejps.2007.12.009

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  45 in total

Review 1.  Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs.

Authors:  Miroslav Dostalek; Fatemeh Akhlaghi; Martina Puzanovova
Journal:  Clin Pharmacokinet       Date:  2012-08-01       Impact factor: 6.447

2.  Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin.

Authors:  Jaekyu Shin; Daniel F Pauly; Michael A Pacanowski; Taimour Langaee; Reginald F Frye; Julie A Johnson
Journal:  Pharmacotherapy       Date:  2011-10       Impact factor: 4.705

3.  Diabetes mellitus reduces the clearance of atorvastatin lactone: results of a population pharmacokinetic analysis in renal transplant recipients and in vitro studies using human liver microsomes.

Authors:  Miroslav Dostalek; Wai-Johnn Sam; Komal R Paryani; Joyce S Macwan; Reginald Y Gohh; Fatemeh Akhlaghi
Journal:  Clin Pharmacokinet       Date:  2012-09-01       Impact factor: 6.447

4.  Impact of CYP2D6 polymorphisms on the pharmacokinetics of lovastatin in Chinese subjects.

Authors:  Ophelia Qi Ping Yin; Valiant Wah Lun Mak; Miao Hu; Benny Siu Pong Fok; Moses Sing Sum Chow; Brian Tomlinson
Journal:  Eur J Clin Pharmacol       Date:  2012-01-27       Impact factor: 2.953

5.  Effects of SLCO1B1 and GATM gene variants on rosuvastatin-induced myopathy are unrelated to high plasma exposure of rosuvastatin and its metabolites.

Authors:  Xue Bai; Bin Zhang; Ping Wang; Guan-Lei Wang; Jia-Li Li; Ding-Sheng Wen; Xing-Zhen Long; Hong-Shuo Sun; Yi-Bin Liu; Min Huang; Shi-Long Zhong
Journal:  Acta Pharmacol Sin       Date:  2018-06-27       Impact factor: 6.150

6.  Atorvastatin metabolite measurements as a diagnostic tool for statin-induced myopathy.

Authors:  Ine B Skottheim; Martin P Bogsrud; Monica Hermann; Kjetil Retterstøl; Anders Åsberg
Journal:  Mol Diagn Ther       Date:  2011-08-01       Impact factor: 4.074

7.  Simvastatin represses protein synthesis in the muscle-derived C₂C₁₂ cell line with a concomitant reduction in eukaryotic initiation factor 2B expression.

Authors:  Alexander P Tuckow; Sarah J Jefferson; Scot R Kimball; Leonard S Jefferson
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-01-11       Impact factor: 4.310

Review 8.  Effects of statins on skeletal muscle: a perspective for physical therapists.

Authors:  Stephanie L Di Stasi; Toran D MacLeod; Joshua D Winters; Stuart A Binder-Macleod
Journal:  Phys Ther       Date:  2010-08-05

9.  UGT1A1*28 is associated with decreased systemic exposure of atorvastatin lactone.

Authors:  Camilla Stormo; Martin P Bogsrud; Monica Hermann; Anders Åsberg; Armin P Piehler; Kjetil Retterstøl; Marianne K Kringen
Journal:  Mol Diagn Ther       Date:  2013-08       Impact factor: 4.074

10.  The SLCO1B1*5 genetic variant is associated with statin-induced side effects.

Authors:  Deepak Voora; Svati H Shah; Ivan Spasojevic; Shazia Ali; Carol R Reed; Benjamin A Salisbury; Geoffrey S Ginsburg
Journal:  J Am Coll Cardiol       Date:  2009-10-20       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.